IMNP
Immune Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 0.0045
- Prev close
- 0.0053
- Mkt cap
- 1.35M
- Vol
- 29.10M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0023
- High
- 0.0051
- Forward P/E
- -0.02
- Beta
- 2.11
- Short ratio
- 1.32
- Inst. own
- 1.81%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.052778
- 200-d avg
- 0.146667
- 1y target
- 0.00
Key statistics
- Market cap
- 1.35M
- Enterprise value
- 7.54M
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.23
- EPS (TTM)
- -1.34
- Beta
- 2.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.56M
- Total cash
- 1.51M
- Total debt
- 7.73M
- Return on equity
- -808.70%
- Shares outstanding
- 44.96M
- Short % of float
- 3.42%
- 50-day average
- 0.052778
- 200-day average
- 0.146667
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 4, 2018 | Maxim Group | init | — | Buy |
| Mar 8, 2015 | Chardan Capital | init | — | Buy |
About Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Major
- Country
- United States
- Website
- immunepharma.com
News
Your note
Sign in to keep a note on IMNP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KAZADO DANIEL | Director | Conversion of Exercise of derivative security | Jul 14, 2015 | 23,048 |
| SIDRANSKY DAVID | Director | Stock Award(Grant) | Jan 7, 2015 | 21,699 |
| TEPER DANIEL GEDEON | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 5, 2016 | 5,865,280 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CVI Holdings, LLC | 0.69% | 251,029 | 47.70K | Jun 29, 2018 |
| Barclays PLC | 0.52% | 187,059 | 35.54K | Jun 29, 2018 |
| Renaissance Technologies, LLC | 0.38% | 138,205 | 26.26K | Jun 29, 2018 |
| Vanguard Group, Inc. (The) | 0.38% | 136,841 | 26.00K | Jun 29, 2018 |
| Edmond De Rothschild Holding S.A. | 0.24% | 88,575 | 16.83K | Jun 29, 2018 |
| Credit Suisse Ag/ | 0.11% | 38,399 | 7.29K | Jun 29, 2018 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.76% | 275,667 | 154.37K | Dec 30, 2017 |
| Vanguard Extended Market Index Fund | 0.38% | 136,241 | 76.29K | Dec 30, 2017 |
| Fidelity Extended Market Index Fund | 0.04% | 15,214 | 2.89K | Jun 29, 2018 |
| Fidelity Total Market Index Fund | 0.02% | 7,141 | 1.36K | Jun 29, 2018 |
| Vanguard Balanced Index Fund | 0.01% | 3,010 | 1.69K | Dec 30, 2017 |